Antibody response to the third dose of inactivated COVID‐19 vaccine in people living with HIV (PLWH): A longitudinal cohort

Abstract The immunogenicity induced by the third dose of inactivated coronavirus disease 2019 (COVID‐19) vaccines in people living with HIV (PLWH) is unclear, and relevant literature is extremely scarce. It is important to add evidence on the humoral immune response induced by the third dose of inactivated COVID‐19 vaccine in PLWH. We collected peripheral venous blood for spike receptor binding domain‐protein specific immunoglobulin G (S‐RBD‐IgG) antibody tests at 28 days after the second dose (T 1 ), 180 days after the second dose (T 2 ) and 35 days after the third dose (T 3 ) of inactivated COVID‐19 vaccines in PLWH. The differences in S‐RBD‐IgG antibody levels and specific seroprevalence among T 1 , T 2 , and T 3 time periods were analyzed, and the effects of age, vaccine brand, and CD4 + T cell count on the levels and specific seroprevalence of S‐RBD‐IgG antibody induced by the third dose in PLWH were examined. The third dose of inactivated COVID‐19 vaccines induced strong S‐RBD‐IgG antibody responses in PLWH. The levels and specific seroprevalence of S‐RBD‐IgG antibody were significantly higher than those at 28 and 180 days after the second dose and were not affected by vaccine brand or CD4 + T cell count. Younger PLWH produced higher levels of S‐RBD‐IgG antibody. The third dose of inactivated COVID‐19 vaccine showed good immunogenicity in PLWH. It is necessary to popularize the third dose in the PLWH population, especially PLWH who do not respond to two doses of inactivated COVID‐19 vaccines. Meanwhile, the durability of the protection provided by the third dose in PLWH must be continuously monitored.